NanoViricides gets anti-HIV effect with shorter drug doses
NanoViricides Inc., a West Haven, Conn., developer of treatments for flu and genital herpes, said that its lead anti-HIV drug candidate has a long-term, anti-HIV effect with a much shorter dosing regimen.
The drug candidate, HIVCide, also showed a markedly lower total drug dose than standard highly active antiretroviral treatment (HAART) triple-drug cocktail therapy in a recent animal trial, the company said. The antiviral effect of HIVCide continued throughout the 48 days of the study, even though the HIVCide dosing was discontinued after 20 days. The company also said the HIVCide’s clinical benefit continued for at least four weeks after the last drug dose.